Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

NCT06694129 is registered in ClinicalTrials.gov with National Cancer Center, China as lead sponsor.

NCT NCT06694129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06694129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
Lead sponsor
National Cancer Center, China
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 1, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, resistance, ros1 gene rearrangement, targeted therapy